BioAtla(BCAB) Newsfilter·2024-12-16 13:00Core Insights - BioAtla, Inc. presented data indicating improved one-year overall survival (OS) for patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) treated with Mecbotamab Vedotin (Mec-V) compared to those with wild-type KRAS (wtKRAS) [1][2] - The one-year OS was reported at 58% for mKRAS patients versus 23% for wtKRAS patients, suggesting Mec-V's potential as a promising treatment option across all KRAS mutation variants [2][3] - A randomized trial of Mec-V in patients with treatment-refractory mKRAS NSCLC is planned for initiation in 2025 based on these findings [2] Company Overview - BioAtla, Inc. is a global clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors [1][4] - The company has two first-in-class CAB programs currently in Phase 2 clinical testing: Mecbotamab Vedotin targeting AXL and ozuriftamab vedotin targeting ROR2 [5] - BioAtla has extensive patent coverage for its CAB technology, with over 780 active patent matters, including more than 500 issued patents [5] Clinical Trial Data - The Phase 2 trial of Mec-V enrolled 78 patients, with 30.7% having mKRAS NSCLC [3] - Among the 21 efficacy-evaluable patients with mKRAS NSCLC, the overall response rate (ORR) was 28.6%, with notable antitumor activity observed across 9 different mKRAS variants [3] - Treatment with Mec-V was well tolerated, showing a manageable safety profile without new safety signals [3] AXL Expression and KRAS Mutation - A strong correlation was confirmed between KRAS mutations and AXL expression, with 70.3% of NSCLC samples harboring any KRAS mutation showing high AXL expression [2][3] - Among the mKRAS G12C variant subset, 81.8% exhibited high AXL expression, reinforcing the relevance of AXL as a therapeutic target [3]